Sector News

Rebel Depomed investor adds former J&J, Abbott execs to proposed board

July 27, 2016
Life sciences

Rebel Depomed investor Starboard Value wants a special meeting as soon as possible–and to get its wish, it’s taking matters into its own hands.

The hedge fund, which owns about 9.9% of the California drugmaker’s outstanding shares, has decided to control the timing of the special meeting, rejecting an offer by Depomed to let it call the meeting itself. As Depomed warned, it’ll be a long process for Starboard to go its own route, but the proxy brawler thinks it’s necessary to “prevent Depomed from any further attempts to manipulate our special meeting process and disenfranchise shareholders with needless stratagems,” its CEO, Jeffrey Smith, wrote in a letter to shareholders.

Starboard also has a couple other picks to tack onto its proposed slate of new Depomed directors, which it hopes to install when the special meeting rolls around: Robert Savage, former worldwide chairman for Johnson & Johnson’s pharma group, and James Tyree, former EVP of pharma products at Abbott Labs. But because revising its nominee lineup would create further delays in setting a meeting date, Starboard is bringing them on as advisers for now.

Along with Starboard’s other board picks–a group that currently includes the fund’s own chief exec, Smith, and former Endo skipper Peter Lankau–Savage and Tyree would create “an all-star board that would work diligently and collaboratively to protect and represent the best interests of shareholders,” Smith wrote.

And that’s not the only roster tweak Starboard wants to make if it successfully turns over the board. It’s willing to include one current Depomed director on the list to “maintain a degree of continuity amidst the required change that we believe is desperately needed at Depomed,” Smith said.

Starboard has been railing on Depomed’s corporate governance practices ever since it first took aim at the pain drug specialist. The hedge fund points to Deposed’s tactics warding off a hostile takeover by Horizon as an act of “egregiously manipulating the corporate machinery to entrench management and the board.”

And the latest request from Depomed–to let it call the special meeting after Oct. 28, when patent litigation over key drug Nucynta would be all wrapped up–didn’t do much to restore Starboard’s faith.

The way Depomed sees it, though, shareholders need all the facts surrounding Nucynta’s patent life to make an “informed voting decision,” it said last month.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach